The open index of psychedelic research

ArticlePsilocybin

Perceptions and Attitudes on Psilocybin-Assisted Therapy among Underrepresented People with Cancer.

Miller M, Meyers M, Oglesby-Adepoju C +2

PreprintLSD

Psychedelic Hormesis: LSD Activates Adaptive Stress Transcriptional Programs in the Prefrontal Cortex

Savino A, Liaci C, Merlo GR +3

Clinical research progress of esketamine in perioperative neuroprotection: from mechanisms to therapeutic neuroprotection.

Wang H, Zhou C, Qu Y +1

Esketamine and Tracheal Extubation Time: Are the Meta-Analytic Estimates Reliable?

Wu JH, Chen PF, Ho CH

Samm50 downregulation-driven mitochondrial dysfunction triggers ferroptosis and contributes to ketamine-induced neurotoxicity and cognitive impairment.

Li Y, Dai X, Hu J +7

Employment-Related Risks in a Clinical Trial of Psychedelic Treatment for Chronic Pain.

Dawson L, Cohen AD, Wilfond B +1

Validating and creating a short-form of the persisting effects questionnaire: A measure of positive and negative outcomes from psychedelic experiences.

Ehrenkranz R, Sepeda ND, Goldy SP +4

Factors for Assessing Employment-Based Risks of Participation in Psychedelic Research.

Topazian RJ, DiStefano MJ, Morales G +1

ArticlePsilocybin

High ventilation breathwork as a non-pharmacological model for inducing psychedelic-like states: expert evaluations of therapeutic potential and risk.

Lueken U, Dziobek I, Havenith MN +2

ArticlePsilocybin

Psilocybin restores social novelty investigation in male SAPAP3 knockout mice and engages prefrontal-hippocampal circuitry.

Gattuso JJ, Bezcioglu B, Hendey J +5

Add-on intravenous ketamine eliminates treatment lag period in severe non-treatment-resistant major depression: Rapid antidepressant and anti-suicidal effects - A randomized controlled trial.

Prakash A, Mahapatra P, Pattnaik JI +2

Default mode network functional connectivity following treatment with conventional antidepressants and (es)ketamine in major depressive disorder: A systematic review.

Lima Constantino J, de Jager JE, Nuninga JO +3

In reply: Methodological considerations in the ketamine and rebound pain meta-analysis.

Khurana BJK, Makkar JK, Singh PM +1

Ketamine metabolite HNK ameliorates anhedonia symptom in Alzheimer's disease mice.

Yang S, Guo B, Deng D +2

Comment on "Ketamine and rebound pain after regional nerve block: Methodological considerations".

Prasad A

Esketamine for treatment of depression in Huntington's disease: A case report.

Saft C, Jessen J, Kiefner D +1

PreprintPsilocybin

Development and Psychometric Validation of the ‘Psychedelic Flourishing Scale’

Pattisson F, Kamboj S, Stoliker D +1

Risk of ketamine exposure in individuals at clinical high-risk for psychosis.

Myers AW, Bertrand CE, Mittal VA

Neuroinflammation in postoperative cognitive dysfunction: the multi-target potential of esketamine in modulating microglial responses and synaptic integrity

Li H, Lin G, Xing W +2

Equipotent Doses and ED95 Extrapolation: Methodological Concerns in Trials of Ciprofol-Esketamine/Sufentanil for Elderly ESD [Letter].

Li L, Zhang Z, Wang Z +1

Structure-based design of subtype-selective psychedelic analogs.

Li H, Tang L, Zhang J +8

Comparison of the efficacy of different interventions for rebound pain after brachial plexus block in upper extremity surgery: A systematic review and network meta-analysis.

Ma W, Chen L, Zhou D +2

Emergent multiscale organisation of neural dynamics fragments in anaesthesia.

Milinkovic B, Seth AK, Barnett L +2